THC Global Group Limited announced that the Australian Therapeutic Goods Administration (TGA) has granted the Company a License to Manufacture Therapeutic Goods for the Southport Facility, more commonly known as a GMP License, completing all licenses required for THC Global to commence commercial manufacture of medicinal cannabis. A GMP License is a mandatory requirement for the commercial manufacture of medicinal cannabis in Australia, and is mutually recognised for supply of pharmaceutical goods in 29 countries across Europe, Asia and North America (Canada). The GMP License authorises the Company to manufacture: Active Pharmaceutical Ingredient (API) extracts; formulation and packaging of medicines; on-site testing and analysis; and supply of medicinal cannabis for human trials in Australia and globally. The Company's Southport Facility is the pharmaceutical bio-floral extraction facility in the Southern Hemisphere and is one of the pharmaceutical GMP licensed facilities for the manufacture of medicinal cannabis. With the receipt of the GMP License, THC Global will now seek to complete negotiations for the export supply of cannabis medicines. The European design and equipment origin of the Southport facility meets key requirements for entering the rapidly expanding European market, differentiating THC Global from almost all established cannabis companies internationally.